DRUG REPURPOSING FOR LUPUS NEPHRITIS THERAPY

Descripción

UNMET NEED:

There is not a current effective and safe treatment for lupus nephritis

PROPOSED SOLUTION:

Therapeutic switching drug to normalize renal function with less side effects

FEATURES:

  • Less side effects than the standard of care
  • Already approved for human in other medical indications (Reprofiling)
  • Market with 1 approval in last 50 years

Aplicaciones

Our compound is a lupus nephritis therapy that aims to normalize renal function or, at least, to prevent the progressive loss of renal function.

Therapy

differs depending on the pathologic lesion. It might also be important

for the treatment of other SLE manifestations, or even other autoimmune

diseases.

Estado de protección

In vitro assays, compound X has been shown to

reduce the expression of co-stimulation and maturation markers from

inflammatory monocyte-derived dendritic cells.

Moreover,

in the LN murine model (LZB/LZW F1 mice), oral administration of

compound X after the beginning of disease (week 30 of age) was able to

significantly delay the onset and to reduce the level of proteinuria (to

improve renal function) compared to non-treated LZB/LZW F1 mice. This

translated to: 1) preservation of weight with age; and 2) 100% survival

compared to non-treated LZB/LZW F1 mice (8% survival) at the end of the

study (330 days). All these results show that the technology is ready

for clinical trials.

IP status: Patent application ongoing

Cooperación que se desea

Co-development

License agreement

Investment